research Alopecia Universalis Unresponsive to Treatment with Tofacitinib: Report of a Case with a Brief Review of the Literature
Tofacitinib helped psoriasis but not alopecia universalis, needing more research.
Search
for
Sort by
Research
120-150 / 399 results
research Janus Kinase Inhibitors for Alopecia Areata
JAK inhibitors offer new hope for treating severe alopecia areata.
research Emerging Drugs for the Treatment of Alopecia Areata
New drugs for alopecia areata show promise but aren't universally effective, and hair loss often returns after stopping treatment.
research Shedding Light on Therapeutics in Alopecia and Their Relevance to COVID-19
Some alopecia treatments might help treat COVID-19, but more research is needed.
research Alopecia Areata: Case Report and Review of Pathophysiology and Treatment with JAK Inhibitors
JAK inhibitors like tofacitinib may effectively treat Alopecia Areata.
research Case Report: Reversal of Long-Standing Refractory Diffuse Non-Scarring Alopecia Due to Systemic Lupus Erythematosus Following Treatment With Tofacitinib
A patient with lupus and long-term hair loss saw significant hair regrowth after using the drug tofacitinib.
research Janus Kinase Inhibitors Versus Other Biological Treatments in Alopecia Areata
Janus kinase inhibitors show promise in treating alopecia areata but need more safety research.
research Inhibition of T-Cell Activity in Alopecia Areata: Recent Developments and New Directions
New treatments targeting T-cell pathways are needed for better alopecia areata management.
research JAK Inhibitors for the Treatment of Alopecia Areata
JAK inhibitors may become the first approved treatment for alopecia areata if they are proven safe and effective.
research The Latest Trends of Treatment for Alopecia
Finasteride, Dutasteride, and Minoxidil are effective for hair growth, while new treatments like laser therapy and PRP show promise with few side effects.
research Safety of Janus Kinase Inhibitors in Patients with Alopecia Areata: A Systematic Review
JAK inhibitors for alopecia areata are linked to minor side effects like headache and acne, but not to an increased risk of serious adverse events.
research Alopecia – New Building Blocks
New treatments for hair loss are emerging, and doctors need to learn how to use them effectively.
research Janus Kinase Inhibitors for Alopecia Areata: A Narrative Review
Janus kinase inhibitors can regrow hair in alopecia areata but may cause side effects and hair loss may return if treatment stops.
research Adverse Events in Patients Treated With Jak-Inhibitors for Alopecia Areata: A Systematic Review
JAK-inhibitors for alopecia areata are generally safe with mostly mild side effects and a low rate of treatment withdrawal.
research Novel Janus Kinase Inhibitors in the Treatment of Dermatologic Conditions
JAK inhibitors show promise for treating various skin diseases.
research Alopecia Areata: Burden of Disease, Approach to Treatment, and Current Unmet Needs
Current treatments for Alopecia Areata have mixed success, and there's a need for better, more accessible options and support for affected individuals.
research Alopecia Areata: Diagnostic and Therapeutic Recommendations of the Polish Society of Dermatology. Part 2: Treatment
The Polish Society of Dermatology recommends treatments for alopecia areata that vary by severity, including topical and systemic medications, with long-term maintenance important for management.
research Novel Investigational Drugs for Alopecia Areata and Future Perspectives
JAK inhibitors are safe and effective for treating moderate-to-severe alopecia areata.
research Alopecia Areata: Time for Position Statement to Include New Systemic Therapeutic Advances
New treatments for severe alopecia areata, especially JAK inhibitors, are recommended as first-line therapy.
research Treatment of Lichen Planopilaris With Janus Kinase Inhibitors
Janus kinase inhibitors may help treat lichen planopilaris.
research Tumor Necrosis Factor Inhibitors and Janus Kinase Inhibitors in the Treatment of Cicatricial Alopecia: A Systematic Review
Tofacitinib and adalimumab are promising treatments for cicatricial alopecia with few side effects.
research Visualizing Severity Of Alopecia Tool Scores In The Clinical Setting Using Patient Images From A Clinical Trial
The study helps doctors use patient images to understand and apply SALT scores for treating severe alopecia areata.
research Use of Ritlecitinib for the Treatment of Alopecia Areata
Ritlecitinib effectively treats alopecia areata in patients 12 and older with fewer side effects.
research Clinical Guidelines of Ukrainian Hair Research Society: Diagnosis and Treatment of Alopecia Areata
The guidelines suggest using various treatments, including antidepressants and steroids, for alopecia areata and discuss the condition's genetic and immune aspects.
research Characterization of a Murine Model of AA Induced by Adoptive Transfer of Cultured Lymph Node Cells
The study developed a mouse model for Alopecia Areata that responds to treatment, useful for future research.
research Scarring Alopecia Is Driven by the Collapse of EGFR-Protected JAK-STAT1-Sensitive Stem Cell Immune Privilege
Cancer treatment drugs can cause permanent hair loss by damaging hair follicle stem cells, but a specific inhibitor might reverse this effect.
research Advances In The Mechanism And New Therapies Of Alopecia Areata
New treatments targeting the JAK signaling pathway, especially JAK inhibitors, show promise for alopecia areata.
research Efficacy of Janus Kinase Inhibitors in Adult Patients With Alopecia Areata
Janus kinase inhibitors are effective and generally safe for treating hair loss in adults with alopecia areata.
research Patient Experience of Off-Label Janus Kinase Inhibitor Use for Alopecia Areata in a Cohort of 34 Patients From a Single UK Practitioner: Exploring Changing Trends in Healthcare Provision and Access to Drug Treatments
Patients with alopecia areata face challenges accessing Janus kinase inhibitors, but some see positive results.
research Drug News and Therapeutic News
JAK inhibitors help treat some diseases but may increase risks of blood clots and cancer in certain patients.